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have the potential to improve on current pre-clinical safety regimes by providing detailed
mechanistic information of altered cellular processes. Here we investigated the added benefit
of integrating transcriptomics, proteomics andmetabolomics togetherwith pharmacokinetics
for drug testing regimes.
Cultured human renal epithelial cells (RPTEC/TERT1) were exposed to the nephrotoxin
Cyclosporine A (CsA) at therapeutic and supratherapeutic concentrations for 14 days.
CsA was quantified in supernatants and cellular lysates by LC–MS/MS for kinetic
modeling. There was a rapid cellular uptake and accumulation of CsA, with a non-
linear relationship between intracellular and applied concentrations. CsA at 15 μM
induced mitochondrial disturbances and activation of the Nrf2-oxidative-damage and
the unfolded protein-response pathways. All three omic streams providedKeywords:
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181J O U R N A L O F P R O T E O M I C S 7 9 ( 2 0 1 3 ) 1 8 0 – 1 9 4complementary information, especially pertaining to Nrf2 and ATF4 activation. No stress
induction was detected with 5 μM CsA; however, both concentrations resulted in a
maximal secretion of cyclophilin B.
The study demonstrates for the first time that CsA-induced stress is not directly linked
to its primary pharmacology. In addition we demonstrate the power of integrated omics
for the elucidation of signaling cascades brought about by compound induced cell
stress.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Failures of lead candidates in the late phases of pharmaceu-
tical development are costly, both in terms of time and
money and thus seriously hinder the number of compounds
reaching the market. Compounds are dropped late in
development, due to a lack of efficacy or to unexpected
adverse effects that were not identified by animal test
batteries. The EU 7th Framework project, Predict-IV, was
established in order to develop mechanistic strategies for
predictive toxicology. We are pursuing three avenues simul-
taneously in an attempt to improve pre-clinical safety test
systems by: (i) focusing on cells of human origin, (ii) conducting
in-depth characterization of molecular perturbations with
complimentary omic technologies and (iii) determining the
actual compound exposure through pharmacokinetic modeling.
Developments in cell culture techniques such as the
availability of hormonally defined media together with
recent advances in immortalization including stable ex-
pression of the catalytic subunit of human telomerase have
led to the generation of improved cell lines such as the
human renal proximal tubular cell line, RPTEC/TERT1 [1].
However, cell cultures have not yet reached their full
potential as a tool for toxicological investigations, as they
have been mostly used in conjunction with cytotoxicity
end-points providing little mechanistic information. Mo-
lecular analysis of cellular processes in response to com-
pound exposure would better harness the potential of in
vitro systems. Recent technological advancements allow the
possibility of a holistic, mechanistic approach to in vitro
toxicology and promise to further our understanding of how
cells deal with stress.
Omic-profiling-techniques have proven to be powerful new
tools for unraveling complex biological processes and have
been successfully utilized in the fields of microbiology, fungal,
plant and human biology [2–5]. Transcriptomic (TCX) studies
cover the entire human genome and are well established. TCX
has beenused inmany in vitro and in vivo studies [6–9]. However,
gene expression alone does not provide information on
alternative splicing, PTM or even protein expression itself.
Proteomics (PTX) offers the possibility to directly study the
expressed protein, including isoforms and PTMs. However, it is
not yet possible to study the entire proteome and factors such
as protein abundance level, pI and solubility, come into play.
Thus the number of proteins detected is dependent on the
protocols employed for isolation, enrichment and separation.
Metabolomics (MTX) provides a snapshot of the metabolic
environment that is the consequence of the transcriptome,
proteome and nutritional environment. Both PTX and MTX arenow beginning to be utilized in toxicological and pharmaco-
logical settings [10,11]. The integration of these three omic
technologies has the potential to give a much more detailed
view of cellular homeostasis than when used individually
[12]. In addition, for a correct interpretation of toxicological
data, it is critical to have information on the cellular handling
of the applied compound. This can be approached using
pharmacokinetic modeling [13].
The major aim of this study was to investigate the benefit
of integrating omic data streams with pharmacokinetics for
use in in vitro toxicology and safety assessment. We show,
under our experimental settings, that this approach provided
a global picture of compound-induced stress and could clearly
distinguish pharmacological from toxicological effects.2. Materials and methods
Chemicals were purchased from Sigma Aldrich, unless other-
wise stated.
2.1. Cell culture
RPTEC/TERT1 [1] cells were obtained from Evercyte GmbH,
Vienna and cultured in a 1 to 1 mixture of DMEM and Ham's
F-12 nutrient mix (Invitrogen) supplemented with 2 mM
glutamax (Invitrogen), 5 μg/ml insulin, 5 μg/ml transferrin and
5 ng/ml sodium selenite, 100 U/ml penicillin and 100 μg/ml
streptomycin, 10 ng/ml epithelial growth factor and 36 ng/ml
hydrocortisone.
2.2. Cell treatment and sample preparation
RPTEC/TERT1 cells were cultured on 0.2 μm pore size, 25 mm
diameter aluminum oxide filters (Nunc), with 1 ml apical and
2 ml basolateral medium. CsA (Calbiochem, purity 97%) was
dissolved in DMSO and further diluted in culture medium to 5
and 15 μM. DMSO concentration was 0.1% in both CsA
medium and control medium. After a 10 day stabilization
phase, cells were treated with CsA every day for up to 14 days.
Cells were harvested at days 1, 3 and 14 for TCX, PTX, andMTX
(Fig. 1a). Additionally, supernatant was collected daily for
MTX and CsA was measured in supernatants, cell lysates and
on cell culture walls (Fig. 1a). RNA was extracted using the
RNeasy Mini Kit (QIAGEN). For PTX, MTX and kinetics ice cold
100% methanol was used as a quenching and lysing reagent.
For MS MTX cells were washed in ammonia bicarbonate
(185 mM, pH 7.8) prior to lysing. CsA bound to cell culture
wells was removed with 100% methanol.
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Fig. 1 – Experimental layout and effects of treatment on monitoring endpoints. (a) Scheme of experimental procedure and
sample generation. RPTEC/TERT1 cells, cultured on microporous supports, were stabilized for 10 days and treated with CsA.
Samples were harvested at set intervals as indicated. Transepithelial electrical resistance (TEER) (b) and lactate (c) were
measured daily. Values represent the mean±SEM of three biological replicates. *Denotes a significant difference (0.05) from
controls using repeated measures two-way ANOVA with a Bonferroni's multiple comparisons post test.
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Transepithelial electrical resistance (TEER) wasmeasured using
the Endohm and EVOM systems from World Precision In-
struments. Supernatant lactate was quantified using a bio-
chemical assay [14]. Statistical analysis was performed using a
two-wayANOVAwith aBonferroni'smultiple comparisonspost
test (n=3).
2.4. Omic and CsA quantification procedures
TCX was conducted with Illumina® HT 12 v3 BeadChip arrays
(~47,000 transcripts). Peptides for PTX were labeled with iTRAQ
and measured with HPLC-MS. The HPLC system was directly
coupled to a linear ion-trap Orbitrap mass spectrometer (LTQ
Orbitrap XL, ThermoFisher Scientific) with a nanoelectrospray
ionization source operated in positive ionization mode. MS MTX
profiling of cell lysateswas also conductedwithOrbitrapMSwith
direct infusion. 1HNMRspectra fromcell lysateswere recorded at
600.13 MHz on a Bruker DMX 600 Spectrometer equipped with a
5 mm DCH cryoprobe at 303 K. Supernatant medium was
analyzed by LC–MS, where separation was performed on an
Ultimate 3000 liquid chromatography system (Dionex) followed
by on-line analysiswith anOrbitrapmass spectrometer. CsAwas
quantified by LC–MS/MS using a calibration curve with a linear
range between 10 nM and 2000 nM.
Detailed procedures are given in the SupplementaryMethods.2.5. Western blot analysis
For cyclophilin B blots, methanol extracts were evaporated
and resuspended in 30 mM Tris–HCl, 7 M urea, 2 M thiourea
and 4% (w/v) CHAPS, pH 8.5. Cell lysates (5 μg) and superna-
tants (16 μl) were loaded. In order to study the nuclear and the
cytosolic fraction RPTEC/TERT1 cells cultured in 12 well plates
were treated every day for up to 14 days with 5 and 15 μM CsA
and with 5 μM of the Nrf2 activator AI1. Cells were lysed and
nuclear and cytosolic fractions were prepared as previously
described [6]. Samples (10 to 20 μg) were separated on a 4–12%
gradient Nu-Page Bis-Tris SDS-PAGE gel and transferred to
PVDFmembranes. Antibody sources and dilutions are given in
the Supplementary Methods.
2.6. Data warehousing, data analysis and statistics
Collection and warehousing of omic data were performed
using BASE (Emergentec Biodevelopment GmbH, www.
emergentec.com). Identification of deregulated TCX probes
was carried out using a moderated one-way ANOVA to reduce
the set of relevant probes to those that exhibit a significant
change under any condition with a Benjamini–Hochberg
corrected p-value below or equal to 0.05. On the remaining
probes, a moderated two-sided t-test was calculated and
corrected via Benjamini–Hochberg. For both steps, the R
package “limma” was used. Pathway and transcription factor
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(IPA®, www.ingenuity.com/), using a fold cutoff of 1.5 and
p-value of 0.001. Heat maps were generated with Treeview
(rana.lbl.gov/EisenSoftware). Principal component analysis
(PCA) plots were generated using prcomp in the R package
“stats”.
Protein identification and quantification workflow were
implemented in OpenMS (version 1.9) [15] and TOPPAS [16].
Statistical analysis was performed using the isobar package [17]
and custom R code. For additional details see the Supplemen-
tary Methods.
The software package BRB-ArrayTools was used to iden-
tify significantly altered features in the supernatant MTX
data [18]. A class comparisonwith less than 0.001 p-value and
2 fold alteration from treated to time matched control was
used.
2.7. Pharmacokinetic analysis
To analyze the in vitro pharmacokinetic CsA data, we
developed a 3-compartmentmodel of CsA exchange between
supernatant, cells and vial wall (Fig. 5a). CsA could distribute
inside the cells, attach to the plastic vial walls and be
metabolized. Several mathematical forms for exchange
rates were tested: the best fit was obtained using a first
order entry into cells with Michaelis–Menten (saturable) exit
rate, a first order attachment to vial wall with non-integer
(fractal) order detachment, and Michaelis–Menten metabo-
lism. For further details see the Supplementary Methods.3. Results
We aimed to investigate the effects of repeated exposure of
Cyclosporine A (CsA) at concentrations where no major
cellular perturbations are observed (upper therapeutic
index) and where severe perturbations are observed, but in
the absence of cell death. Previous experiences demonstrat-
ed that a 14 day repeated dose regime of 5 and 15 μM would
fit these criteria [14]. TEER and lactate production were
monitored through-out the experiment as parameters of
monolayer integrity and cell stress, respectively [14,19]. We
observed an early increase in TEER with 15 μM CsA that was
significantly elevated at day 7 and this elevation was
maintained until day 14 (Fig. 1b). Such an effect has been
previously documented [20] and is thought to be due to
alterations in claudin expression. In our TCX data, we have
also observed such changes. There was no significant impact
of 5 μMCsA on TEER over the 14 days. Lactate productionwas
unaltered by 5 μM CsA but was significantly elevated by
15 μM CsA, starting at day 1 (Fig. 1c). Thus, two independent
parameters demonstrated a major perturbation of cellular
function with 15 μM CsA in the absence of significant
toxicity.
3.1. TCX alterations
Apart from one gene (the chloride channel, CLCNKA, d1 vs d14),
there were no time-dependent alterations in the control
samples. This illustrates the stability of the model over thetreatment period. CsA at 5 μM had no significant impact on the
transcriptome. For 15 μM CsA, there were 3314, 3968 and 1337
probes differently expressed at 1, 3 and 14 days, respectively.
PCA confirmed these observations (Fig. 2a). The highest
transcriptomic impact was observed after 3 days, while
14 days had the least impact. Pathway analysis, using IPA®
identified protein ubiquitination, Nrf2-mediated-oxidative-
stress response, glutathione metabolism and aminoacyl-tRNA
biosynthesis as major hubs (Fig. 2b). Transcription factor
enrichment analysis showed a predominance of Nrf2, XBP1
and ATF4 activation at all time points (Fig. 2c). Individual gene
changes from these pathways are depicted in Fig. 2d as heat
maps.
There was a clear activation of all three branches of the
unfolded protein response (UPR) with 15 μM CsA. Genes that have
been well characterized from the PERK/ATF4 branch include
those involved in amino acid synthesis, amino acid transport
(including SLC7A5 and 11) and aminoacyl-tRNA synthesis
(Fig. 2d). There was also a clear activation of the UPR-ATF6-
branchwith induction ofHSPA5, XBP1 HSP90B1,DDIT3 andWFS1.
The UPR IRE1 branch/XBP1 was also activated, including induc-
tion of SERP-1, and the DnaJ (Hsp40) homologs DNAJB11 and
DNAJB9.
Nrf2-oxidative-stress-pathway was induced by 15 μM CsA.
Nrf2-dependent genes induced at all time points include genes
involved in glutathione synthesis (GCLM and GCLC), glutathione
recycling (GSR), genes with an anti-oxidant role (SRXN1, TXN,
TXNRD1, SOD1) and iron storage (FTH1) (Fig. 2d).NQO1 and heme
oxygenase 1 (HMOX1, aka HO1) were induced at the early time
points. Additionally, ATF4 mRNA, which is under the transcrip-
tional regulation of Nrf2 [21] was increased.
CsA caused a robust alteration in genes involved in
protein degradation (Fig. 2d). These include those involved
in (i) chaperone activity (DnaJ (Hsp40) homologs and heat
shock protein (HSP) family), (ii) ubiquitination (ubiquitin-
conjugating enzymes (UBE) and ubiquitin specific peptidases
(USP)), (iii) proteasome activity (proteasome (prosome,
macropain) subunits (PSM)) and (iv) lysosomal activity (PSAP
and CTSD).
CsA (15 μM) also resulted in an alteration of genes involved
in glycolysis and the p53 pathway. These included the induction
of hexokinase 2 (HK2), enolase 2 (ENO2), CDKN1A (aka p21) and
growth arrest and DNA-damage-inducible, alpha (GADD45A).
Members of the peptidylprolyl isomerase family (PPI),
better known as cyclophilins (CyP), were also altered in the
TCX data by 15 μM CsA (Fig. 2d). The cytosolic isoform CyP-C
(aka PPIC) was decreased on all days. Themitochondrial CyP-D
(encoded by PPIF) and CyP-G (aka PPIG) were increased at day 3
and CyP-H (aka PPIH) was decreased at day 1.
3.2. PTX alterations induced by CsA
A total of 218 out of 2642 proteins detected, of which 599 were
detected in every condition, were significantly altered by 15 μM
CsA. PCA shows a strong separation of both concentrations
(Fig. 3a). The fold expression levels of 15 μM CsA-altered
proteins were correlated to their respective mRNA values at
each time point (Fig. 3b). Day 1 had the poorest correlation that
improved considerablywith time. However, for certain proteins
there was no correlation or an inverse correlation to the
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Fig. 2 – Effects of CsAexposure onRPTEC/TERT1 transcriptome. (a) Principal component analysis (PCA) of all probes from the 27 arrays.
(b) IPA®summaryof enrichedcanonical pathways. The ratio is thenumberof identifiedmoleculesdividedby thenumberofmolecules
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Fig. 3 – Effects of CsA exposure on RPTEC/TERT1 proteome. (a) PCA of all 599 proteins detected in every sample. (b) Correlation of
CsA-induced protein alterationswith correspondingmRNA levels. Red and green dots represent a good correlation of increased or
decreased molecules, respectively. Blue dots show a poor correlation betweenmRNA and protein. (c) Heat map and functional
grouping of proteins, with green indicating a decrease and red indicating an increase in protein abundance over control values.
The mRNA DE (differentially expressed) column reports whether the corresponding mRNA was significantly deregulated.
185J O U R N A L O F P R O T E O M I C S 7 9 ( 2 0 1 3 ) 1 8 0 – 1 9 4transcript level. For example, PIGQ and TIGAR were marginally
altered at the mRNA level but increased at the protein level
(Fig. 3b), whereas PPP1CAwas increased at the protein level butexhibited a decreased transcript level. Additionally, the fatty
acid transporter SLC25A18, and CyP-B (aka PPIB) were only
altered at the protein level. Examples of good correlations
186 J O U R N A L O F P R O T E O M I C S 7 9 ( 2 0 1 3 ) 1 8 0 – 1 9 4between mRNA and protein levels include the decreased
molecules butyrobetaine (gamma), 2-oxoglutarate dioxygenase
(BBOX1) and ATPase, ATP6V1B1 and the increased molecules
MLLT11 and HSPA1A, and SRXN1.
Functional evaluation of the proteins altered by 15 μM CsA
demonstrated a dominance of oxidative stress response,
mitochondrial dysfunction and protein degradation, which
overlaps with the TCX data (Fig. 3c). In the ATF4 pathway,
PPP1CA, ASNS, GARS, IARS and YARS were all induced.
Additionally, there were alterations in chaperone proteins and
proteins involved in translation. For the Nrf2 pathway, proteins
including FTH1, SRXN1, GCLM and GLRX3 were elevated at one
or more time points. Additionally, proteins known to be
attenuated by Nrf2 activation were decreased, for example
SOD3 [22]. A number of proteins not directly linked to Nrf2 but
known to be altered by oxidative stresswere also impactedhere
including, biliverdin reductase B (BLVRB) and oxidation resis-
tance 1 (OXR1). Proteins associatedwith themitochondria were
also altered, including a decrease in cytochrome C oxidase (1
and 2) and an increase in MINOS-1 and MLLT11 (aka Af1q). The
latter protein is thought to be involved in the regulation of
mitochondrial membrane potential [23]. Proteins that are
associated with ubiquitination, proteasome activation (PSMs)
and lysosomal activity (including cathepsin D, CTSD) were
induced (Fig. 3c). Proteins involved in protein synthesis and
energy metabolism were also altered. Fatty acid metabolism
was suppressed, for example, BBOX1 and the long chain fatty
acid transporter SLC27A4 were decreased. Proteins involved in
glycolysis were increased including, ENO2, HK2 and phospho-
fructokinase P (PFKP).
CyP-D was increased at days 3 and 14 (Fig. 3c). Interesting-
ly, CyP-B was the only protein consistently attenuated by both
CsA concentrations at all time points.
3.3. MTX alterations
3.3.1. Extracellular
PCA demonstrated a high impact of 15 μM CsA and a
negligible effect of 5 μM on the metabolic profile in superna-
tant medium (Fig. 4a). The 15 μM samples demonstrated a
time-dependent clustering pattern. There were 192 signifi-
cant features with over 2 fold alteration at any day (Fig. 4b).
At the present time deeper biological insights of the MTX
supernatant data cannot be provided as the data set remains
un-annotated.
3.3.2. Cellular
CsA (15 μM) had a considerable impact on cellular metabo-
lites. Gamma-glutamylcysteine (γ-GC) was the most in-
creased metabolite with an 80-fold induction at day 3
(Fig. 4c). Glutathione (GSH), glutathione disulfide (GSSG)
and cysteine glutathione disulfide (CYSSG) were also
heavily induced, demonstrating an induction of glutathione
synthesis, recycling and oxidation. The amino acids L-alanine,
L-arginine, L-leucine, L-tryptophan, L-valine and L-isoleucine
were increased, while L-aspartate, L-threonine and L-glutamate
weredecreased. Fumaratewasdecreasedwhile citrateandNADH
were elevated. The nucleoside monophosphate sugar cytidine
monophosphate N-acetylneuraminic acid (CMP-NeuNAc) was
increased. CMP-NeuNAc is involved in glycosylation, specificallysialic acid addition, and its induction was paralleled by an
increase in the mRNA for cytidine monophosphate N-
acetylneuraminic acid synthetase (CMAS). Sphingomyelin
was decreased while phosphatidylcholine (o-14:0/16:0) was
increased after 14-day exposure. Finally, the osmolytes
betaine and glycerophosphocholine (GPC) were decreased.
3.4. CsA pharmacokinetics in vitro
CsA was applied daily, thus resetting the concentration to 5 or
15 μM externally every 24 h. The measured CsA concentrations
in the supernatant and cell lysates were superimposed with the
best maximum posterior fit of the 3-compartment pharmacoki-
netic model (Fig. 5a). These predictions were generated from
random, but plausible, parameter values. Overall the data iswell
simulated. The various curves reflect uncertainty in the model
predictions, resulting from unavoidable measurement errors
and modeling approximations. The posterior parameter distri-
butions obtained after Markov-chain Monte Carlo sampling are
summarized in Supplementary Table 1. CsA applied at 5 μM,
demonstrated minor biokinetic alterations between day 0 and
day 13 (Fig. 5b and c). Some adsorption to the plastic occurred
rapidly, accounting for 6.9% of the corresponding quantity in the
supernatant within 30 min and reaching its peak of 12% at 24 h
onday 0. Theunchanged valuesmeasured at day 13 indicate the
saturation of the process. A steady-state regime was quickly
reachedwith approximately 67% of CsA in the supernatant, 21%
in the cells and 12% on the vial walls. The recovery of CsA was
approximately 85% at each time point, indicating that CsA
metabolism is limited.
CsA applied at 15 μM, showed major kinetic alterations
over the time course (Fig. 5b and c), reflected in the increased
uptake half time of 0.38 h on day 0 to 2.9 h on day 13. In
addition there was an extremely high intracellular concen-
tration at day 13, while the kinetics in the supernatant
remained similar at both days. Approximate steady-state
was reached in cells only after about 7 days and the
distribution between supernatant, cells and vial walls was
48, 43, and 9%, respectively. The intracellular concentration
measured at day 13 was 9.3 fold higher than that for 5 μMCsA.
These values represent an abrupt non-linear accumulation of
CsA in cells, with increasing concentrations and could not
have been detected by a single administration. CsA recovery
was approximately 85% at each time point. Plastic binding of
15 μM CsA took longer to saturate than 5 μM, also peaking at
12% (data not shown).
The global metabolomic alterations from Fig. 4b were
superimposed on the cellular kinetic data and follow the time
course of intra-cellular CsA concentrations closely (Fig. 5c,
boxes).
3.5. Cyclophilin B secretion
While PTX analysis revealed that cellular CyP-B was reduced
with both concentrations at all time points (Fig. 3b and c),
there was no alteration in the mRNA level under any
condition (Fig. 3b). Thus, it is likely that CsA is binding CyP-B
resulting in secretion, as previously demonstrated [24].
Therefore, we investigated CyP-B content in cell lysates and
supernatants. CsA induced a time-dependent increase in
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CyP-B (Fig. 6a). The time course and magnitude of these
observations were almost identical for both concentrations.
At 24 h exposure, secretion was maximal and very littleCyP-B was observed in supernatants on subsequent expo-
sure days (not shown). A dose–response relationship dem-
onstrated a maximum secretion with 5.8 μM CsA at 24 h
(Fig. 6b and c).
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by Western blot analysis
Since theNrf2 oxidative stress response and the 26Sproteasome
pathways were both significantly altered, the two transcription
factors Nrf2 andNrf1, aswell as some of their regulated proteinswere investigated inmore detail. In addition, as a representative
protein of the UPR, PERK was also investigated further. Levels of
Nrf2 increased in the nuclear fraction in response to 15 μM CsA
and to theNrf2 inducer AI1 (Fig. 6d). The response peaked at day
3 and returned to basal levels by day 14 for CsA but remained
elevated for AI1. HO1was increased in response to 15 μMCsA in
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NQO1 was increased by AI1 at all time points but only at day 14
with CsA (Fig. 6d). TXNRD1 levels were increased in response to
15 μM CsA and AI1 at all time points. While we found no
evidence for a CsA-induced increase in Nrf1 protein levels or
nuclear translocation, two proteasome proteins of the 26S
proteasome, PSMB7 (beta subunit of the 20S catalytic core) and
PSMC4 (ATPase of the 19S regulatory unit) were increased by
15 μM CsA at all time points. In addition, 5 μM CsA increased
PSMC4 levels slightly at day 14. AI1 on the other hand had no
effect on PSMB7 or PSMC4 expression. PERK was induced with
15 μMCsA at all time points, with highest levels observed at day
3 (Fig. 6d). AI1 did not induce PERK levels indicating an Nfr2
independent effect.4. Discussion
Integrating omic approaches is becoming more important in
cellular and molecular biology and will most likely change the
way we approach biological investigations [4]. However, at-
tempts thus far to combine omic data streams have been met
with limited success [2,25]. In thepresent study,wehavebrought
together experts from the various fields of TCX, PTX, MTX,
epithelial cell culture and pharmacokineticmodeling. Themajor
aim was to investigate the benefit of integrating omic data
streams and pharmacokinetics for application in drug safety,
utilizing an in vitro system treated with CsA in repeat dose.
The discovery of the potent immunosuppressive properties of
CsA revolutionized transplant medicine. Three decades later,
CsA is still one of the leading immunosuppressive agents in
clinical use. However, it was recognized early on that CsA is
nephrotoxic, causing disturbances to the vasculature, the glo-
merulus and the proximal tubule [26–28]. In addition, CsA can
also induce hepatotoxicity and cardiotoxicity [29]. Although it is a
very well studied compound, its exact mechanism of toxicity is
still not settled. Evidence fromboth in vitro and in vivo studies has
implicated CsA-induced reactive oxygen species (ROS) as a
potential toxicity mechanism and co-administration of antioxi-
dants appears to ameliorate nephrotoxic outcome [29,30]. It is
plausible that ROS is mitochondria-derived, especially since CsA
has been shown to cause injury to isolated mitochondria and to
mitochondria both in vitro and in vivo [27,31–34]. Indeed, CsA has
been shown to interfere with the putative mitochondrial
transition pore [35], to increase both inner mitochondrial
membrane potential [36] and mitochondrial calcium loading
[37]. Some of these events are thought to be mediated via CsA
binding andmodification of the mitochondrial protein CyP-D
[38]. Thus, primary mitochondrial injury is an attractive
theory for the harmful effects of CsA and may explain why
cells with high mitochondrial volume fraction, such as
proximal tubular cells, hepatocytes and cardiac myocytes
are targets. Here, 15 μM CsA increased CyP-D mRNA and the
protein was induced at both CsA concentrations. In addition,
15 μM CsA exposure resulted in an early induction of lactate
production, a reduction in cellular fumarate, and an increase
in cellular citrate and NADH. All of these metabolic alter-
ations point to an inhibition of mitochondrial oxidative
phosphorylation.Mitochondrial injury can lead to oxidative stress and indeed
theNrf2-oxidative-stress pathwaywas enriched inall omic data
sets with 15 μM CsA. We observed a robust increase in Nrf2
nuclear translocation and downstream targets, including TXN,
TXNRD1, HO1, NQO1 and SRXN1. A major effect of the Nrf2
defense mechanism is to increase glutathione reserves and
enhance GSSG recycling to GSH, thereby redressing the highly
oxidative environment. There was an obvious impact of CsA
(15 μM) on the glutathione pathway, with an enhanced level of
genes and proteins involved in glutathione synthesis and
recycling (includingGCLM,GCLCandGSR) increasing the cellular
metabolites γ-GC and GSH.
It has also been suggested that CsA-induced proximal
tubular toxicity is a result of ER stress and that ROS generation
is a secondary event [39]. This is supported by a recent study
which shows that antioxidant treatment does not prevent
CsA-induced ER stress in HEK cells [11]. The unfolded protein
response (UPR) is mounted when ER stress is detected and
serves primarily to return normal ER function [40]. All three
branches of theUPRwere induced by 15 μMCsAand therewas a
strong signature of ATF4 activation in all omic data streams.
Activation of PERK results in phosphorylation of the alpha
domain of eukaryotic initiation factor 2 (eIF2), inhibiting its
ability to initiate translation, thereby decreasing the load of
nascent proteins entering the ER [41]. However, due to the
presence of twoupstreamopen reading frames (uORFs) in the 5′
leader of ATF4 mRNA, PERK activation actually increases the
translation of ATF4 [42]. ATF4 is one of themain effectors of the
UPR and promotes the transcription of genes involved in amino
acid synthesis, amino acid transport and aminoacyl-tRNA
synthesis [43]. Protein phosphatase 1 induction is a keynegative
feedback mechanism and acts to reactivate translation, by
dephosphorylating eIF2α [44]. The regulatory subunit of protein
phosphatase 1 (PPP1R15A) was increased in the TCX data and
the catalytic subunit PPP1CA was increased in the PTX data. In
addition, many of the aminoacyl-tRNA synthesis genes and
proteins were induced. Asparagine synthetase (ASNS) was
heavily induced in both TCX and PTX data sets. ASNS catalyzes
the glutamine- and ATP-dependent conversion of aspartic acid
to asparagine [43], producing in the process glutamate, a
precursor for glutathione synthesis. Both glutamate and
glutathione metabolic pathways were severely affected. A
number of amino acid transporters and intracellular amino
acids were induced here. Interestingly, Nrf2 increases ATF4
transcription [21] and thus acts as a primer forUPR. ATF4mRNA
was heavily induced at all time points.
There was a strong induction of the PSM, proteasomal
family members at both the mRNA and protein levels at all
three time points by 15 μMCsA. Such a rigorous induction of
protein ubiquitination and proteasomal degradation is
likely to necessitate removal of oxidized proteins and
would be expected to run in parallel to Nrf2 activation.
There has even been a suggestion that Nrf2 may directly
regulate proteasomal activity [45]. However, under our
experimental conditions this was not the case, as the Nrf2
activator AI1 efficiently activated Nrf2 without increasing
the two proteasomal proteins PSMB7 and PSMC4. Recent
evidence has shown that the proteasome is likely under the
transcriptional control of the related transcription factor,
Nrf1 [46]. Nrf1 was up-regulated here at the transcript level
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cytosolic or nuclear protein levels. Thus it remains unclear
if Nrf1 is directly involved in the proteasomal response
observed here.
Cyclophilins are the primary molecular target of CsA [47]
and the complex of CsA and cyclophilin leads to calcineurin
inhibition and is responsible for the immunosuppressive
effects [48]. Cyclophilins have a peptidyl-prolyl cis–trans
isomerase (PPIase) activity and function as molecular chap-
erones. While all cyclophilin family members bind CsA, only
CsA/CyP-A and CsA/CyP-B have been shown to inhibit
calcineurin activity [49,50]. In the current study, CyP-B was
the most decreased cellular protein identified by PTX at both
CsA concentrations at all time points, while being unaffected
at the mRNA level. Thus, we speculated that CsA exposure
may induce CyP-B secretion as has been previously demon-
strated in other cell culture models [24,51]. Western blot
analysis confirmed that CsA induced CyP-B secretion. Inter-
estingly, CyP-B was found only in the apical compartment,
suggesting polarized secretion. It has been suggested that
calcineurin inhibition is directly involved in the side effects
of CsA [52,53]. However, our results provide compelling
evidence for a calcineurin independent toxicity mechanism,
as both 5 and 15 μM resulted in complete loss of cytosolic
CyP-B, but no cell stress was observed at 5 μM over 14 days
exposure.
The applicability of sensitive high-content omic technol-
ogies and the extraction of meaningful data are highly
dependent on the use of well defined, standardized, stable
and relevant biological systems. The in vitro model we have
employed is first stabilized for 10 days at confluence,
allowing complete contact inhibition. We have shown that
under these conditions there is no longer a time-dependent
alteration in the transcriptome of untreated cells. This is
likely a key factor to the success of the omic comparisons
carried out in this cell model.
An obvious, yet often overlooked, aspect of in vitro ap-
proaches to drug safety assessment is the bioavailability of the
compound and the concentration of the parent compound
within cells as a function of time. Without this information it is
not possible to compare with corresponding in vivo data. Here
weused LC–MS/MS to quantify the distribution of CsAover time
and constructed a pharmacokinetic model. The model de-
scribes a rapid cellular uptake and accumulation of CsA, which
is to be expected for a highly lipophilic compound. Application
of 5 μMCsA resulted in an intracellular steady-state after 2 days
of ~860 μM, while 15 μM reached a steady-state after 7 days, at
an intracellular concentration of ~7600 μM. Thus, there is a
non-linear dose–response relationship of external to internal
CsA concentration due to bioaccumulation of CsA. This may be
related to saturation of the p-glycoprotein extrusion pump at
concentrations above 5 μM. The peak concentration of CsA in
human blood, at therapeutic concentrations, has been reported
to be between 100 and 830 nM [54,55]. However, it is well
established that due to the lipophilicity of CsA, such measure-
ments are highly dependent on factors including BMI, the level
of lipoproteins and hematocrit level. A post-mortem study
calculated that CsA is 53 times higher, on a per weight basis, in
various tissues than accompanying blood samples [56]. Since
we have employed a serum and blood free system, the higheraccumulation of 215 fold for 5 μM CsA is to be expected
(calculated from the average of day 13 measurements).
Tissue-specific toxicities are often due to accumulation in
the target tissue such as the kidney and thus this informa-
tion is critical for safety evaluation. Assessment based on
nominal concentrations in vitro or plasma levels in vivo alone,
is imprecise, as tissue concentrations could be, as shown
here for the high concentration of CsA, far above a safe
threshold.
In summary, the results clearly show that cells are
simultaneously experiencing mitochondrial perturbations,
oxidative- and ER-stress only at the high CsA concentration.
However, CyP-B secretion was maximum already at the low
CsA concentration. This study demonstrates that in vitro cell
culture systems coupled with pharmacokinetics and high
content omic approaches can give extremely detailed and
quantitative insights into both the pharmacological and
toxicological effects of compounds. We also demonstrate
the added value of integrating these techniques as illustrated
in Fig. 7. In addition, the PTX data did not merely mirror the
TCX data, but provided further information on key events,
such as CyP-B secretion that is independent from gene
transcription. MTX data provided an additional level of
information and was particularly useful for assessing
mitochondrial perturbations, a common target of xenobi-
otics. In conclusion, an integrated omic approach com-
bined with stable human-derived in vitro cell culture
models has the potential to considerably advance our
understanding of chemical induced cellular perturbations
and will be an extremely useful approach to drug safety
paradigms.
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